Corbin Therapeutics is a spin-off company from AmorChem Fund 1, developing a sophisticated in-vivo genome-wide screening platform in mice undergoing experimental neuro-inflammation, from the laboratory of Dr Philippe Gros, Faculty of Medicine, McGill University, leading to a novel anti-inflammatory target in the deubiquitinylation (DUB) family of enzymes, more particularly USP15.
Company Details
- Founded
- 2016
- Address
- 4 Westmount Square, 160,canada
- in****@****era.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- corbinthera.com
- Keywords
- neuroinflammation, USP15, DUB, Multiple sclerosis.
- HQ
- Westmount, Quebec
Corbin Therapeutics Inc Questions
Corbin Therapeutics Inc's website is corbinthera.com
Corbin Therapeutics Inc's LinkedIn profile is https://ca.linkedin.com/company/corbin-therapeutics-inc
Corbin Therapeutics Inc's industry is
Biotechnology Research
Corbin Therapeutics Inc's top competitors are
Life Sciences Partnering Canada,
Breaking Bone,
Indero (Formerly Innovaderm),
Raya Therapeutic Inc.,
Hepius Medical,
Endostood,
Gynaware,
Stenoa,
Drdialysis Technologies,
Zenith Epigenetics Ltd..
Corbin Therapeutics Inc's support email address is info@corbinthera.com
Corbin Therapeutics Inc's categories are Biotechnology Research
Corbin Therapeutics Inc's founding year is 2016
